Clinical trials
Phase 1 Lymphoma trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Terminated | 6 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Symphogen A/S | 3 |
| University Health Network, Toronto | 3 |
| AstraZeneca | 2 |
| Children's Oncology Group | 2 |
| Novartis Pharmaceuticals | 2 |
| Treeline Biosciences, Inc. | 2 |
| Alaunos Therapeutics | 1 |
| Bayer | 1 |
| British Columbia Cancer Agency | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma | 40 |
| Lymphoma, Non-Hodgkin | 9 |
| Lymphoma, Large B-Cell, Diffuse | 8 |
| Hodgkin Disease | 7 |
| Neoplasms | 7 |
| Recurrence | 7 |
| Burkitt Lymphoma | 6 |
| Leukemia | 6 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Lymphoma, Mantle-Cell | 5 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.